Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Trial of Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma

NCT04850495 is registered in ClinicalTrials.gov with Yazeed Sawalha as lead sponsor.

NCT NCT04850495
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04850495 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Trial of Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma
Lead sponsor
Yazeed Sawalha
Phase
Phase 1
Overall status
Active, not recruiting
Start date
November 16, 2021
Completion date
December 15, 2026
Enrollment
38 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma, transformed follicular lymphoma to diffuse large b-cell lymphoma, transformed marginal zone lymphoma to diffuse large b-cell lymphoma